Korean botulinum toxins

Area of Science:

• Biotechnology
• Pharmaceuticals
• Dermatology

Background:

• Botulinum toxin (BT) has been used therapeutically since the late 1980s.
• Initially dominated by European and US manufacturers, the BT market expanded significantly with the rise of aesthetic applications.
• Numerous new manufacturers, particularly from South Korea, have entered the field.

Purpose of the Study:

• To provide an overview of the rapidly expanding and diversifying botulinum toxin (BT) landscape in South Korea.
• To detail the number of Korean manufacturers and BT drugs registered.
• To highlight key products and their market status.

Main Methods:

• Review of registered botulinum toxin (BT) drugs in South Korea.
• Categorization of drugs by class, manufacturer, and indication (domestic/export).
• Identification of drugs undergoing clinical studies in international markets.

Main Results:

• South Korea has 15 manufacturers with 19 BT drugs registered, primarily for aesthetic uses.
• Includes 2 Class 1 drugs (PrabotulinumtoxinA, LetibotulinumtoxinA) approved in Korea, USA, and Europe.
• Features 12 Class 2 drugs (e.g., Neuronox®, Innotox®, Coretox®) for domestic and export markets, with Innotox® and Toxsta® in US clinical trials.
• Additionally, 5 Class 3 drugs are registered for export only.
• 5 manufacturers have 5 drug projects in advanced development phases.

Conclusions:

• South Korea leads globally in the number of botulinum toxin (BT) manufacturers and drugs.
• The Korean BT market is characterized by rapid expansion and diversification, particularly in aesthetic indications.
• Korean BT products are gaining international recognition and market presence, with significant ongoing development.